Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies

Alianda Camesi; Reto Wettstein; Ezra Valido; Nicole Nyfeler; Stevan Stojic; Marija Glisic; Jivko Stoyanov; Alessandro Bertolo

doi:10.1177/20417314231201071

Advancements in cell-based therapies for the treatment of pressure injuries: A systematic review of interventional studies

J Tissue Eng. 2023 Nov 20:14:20417314231201071. doi: 10.1177/20417314231201071. eCollection 2023 Jan-Dec.

Authors

Alianda Camesi¹, Reto Wettstein^{1

2}, Ezra Valido^{1

3}, Nicole Nyfeler¹, Stevan Stojic⁴, Marija Glisic^{4

5}, Jivko Stoyanov^{1

5}, Alessandro Bertolo^{1

6}

Affiliations

¹ SCI Population Biobanking & Translational Research Group, Swiss Paraplegic Research, Nottwil, Switzerland.
² Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital of Basel, Basel, Switzerland.
³ Department of Health Sciences, University of Lucerne, Lucerne, Switzerland.
⁴ Cardiometabolic and Respiratory Research, Swiss Paraplegic Research, Nottwil, Switzerland.
⁵ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
⁶ Department of Orthopaedic Surgery, University of Bern, Bern Inselspital, Bern, Switzerland.

Abstract

The high recurrence and complications associated with severe pressure injuries (PI) necessitate the exploration of advanced treatments, such as cell-based therapies, to facilitate wound healing. Such techniques harness the ability of different cell types to promote angiogenesis, re-epithelialization of the skin, and tissue regeneration. This systematic review explores the efficacy of cell-based therapies and tissue engineering in treating deep PI. We searched for interventional studies using cells in the treatment of PI in adults in four online libraries (PubMed, Embase, Ovid Medline, and Cochrane; latest search 10th June 2023). We found one randomized clinical trial (RCT), two non-RCT, and three pre-post studies, comprising 481 study participants with PI (253 intervention/228 controls). The risk of bias was categorized as moderate due to minimal bias in outcome measurements, or high owing to unclear patient randomization methods, as assessed by the ROBINS-I, NIH, and RoB-2 tools. Four cell types were identified in the context of cell-based therapies of PI: bone marrow mononuclear stem cells (BM-MNCs, n = 2); hematopoietic derived stem cells (HSC, n = 1); macrophages and activated macrophage suspensions (AMS, n = 2); and cryopreserved placental membrane containing viable cells (vCPM, n = 1). Wound healing outcomes were observed in patients undergoing cell-based therapies, including complete wound closure (AMS, vCPM; n = 142), faster healing rate (BM-MNCs, AMS; n = 146), improved granulation tissue formation (HSC, n = 3) and shorter hospitalization time (BM-MNCs; n = 108) compared to standard of care, with no adverse reactions. PI healing rate decreased only in one study with BM-MNC therapy, compared to control (n = 86). Based on the available data, though with limited evidence, it seems that macrophage deployment showed the most favorable outcomes. The results indicate that cell-based therapies offer a potential avenue for enhancing wound healing and tissue repair in PI; however, more extensive research is needed in this domain.

Keywords: Pressure injuries; cell-based therapies; systematic review; wound healing.

Publication types

Review